Nutritional approaches to modulate oxidative stress in Alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 5, 2011, Pages 452-469

  Pocernich, C B ^a   Lange, M L B ^a   Sultana, R ^a   Butterfield, D A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

glutamylcysteine ethyl ester; Alzheimer's disease; Amyloid peptide; Curcumin; Epigallocatechin gallate; Ferulic acid; Glutathione; Lipoic acid; N acetylcysteine; Quercetin; Resveratrol; Vitamin e

Indexed keywords

ACETYLCYSTEINE; ACROLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CORN OIL; CURCUMIN; CYSTEINE; DEOXYGLUCOSE; DIHYDROLIPOATE; EPIGALLOCATECHIN GALLATE; FERULIC ACID; GAMMA GLUTAMYLCYSTEINE ETHYL ESTER; GAMMA TOCOPHEROL; GLUCOSE TRANSPORTER; GLUTATHIONE; LIPOFUSCIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MEMBRANE METALLOENDOPEPTIDASE; QUERCETIN; RESVERATROL; SOYBEAN OIL; SUPEROXIDE DISMUTASE; THIOCTIC ACID; THIOFLAVINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIOSYNTHESIS; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN ISCHEMIA; CALORIC RESTRICTION; CELL DEATH; CELL SURVIVAL; CHELATION; CLEARANCE; COGNITION; COGNITIVE DEFECT; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG ABSORPTION; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ESTERIFICATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; HUMAN; HYDROPHOBICITY; INDIA; LIPID PEROXIDATION; LIPOPHILICITY; LIVER; LOW DRUG DOSE; MEMORY DISORDER; METHYLATION; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NERVE DEGENERATION; NONHUMAN; NUTRITION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIDE EFFECT; SINGLE DRUG DOSE; SKILL; SMALL INTESTINE; SPLEEN; SULFONATION; TEA; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BRAIN; DIET; DIETARY SUPPLEMENTS; HUMANS; OXIDATIVE STRESS;

EID: 79959922360     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796391908     Document Type: Article

References (258)

1. Selkoe DJ. Alzheimer's disease results from the cerebral accumula tion and cytotoxicity of amyloid P-protein. J Alzheimers Dis 3: 75-80 (2001).
2. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, la du MJ. Oligomeric and fibrillar species of amyloid-P peptides differentially affect neuronal viability. J Biol Chem 277: 32046-53 (2002).
3. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurode-generation: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-98 (2003).
4. Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA. Elevation of mitochondrial glutathione by γ-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J Neurosci Res 74: 917-27 (2003).
5. Fawzi NL, Okabe Y, Yap EH, Head-Gordon T. Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1-40) peptide. J Mol Biol 365: 535-50 (2007).
6. Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid P-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J 355: 869-77 (2001).
7. Shen J, Kelleher RJ. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104: 403-9 (2007).
8. Suh YH, Checler F. Amyloid precursor protein, presenilins, and asynuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525 (2002).
9. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 38: 678-80 (1995).
10. de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, et al. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: Relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging 21: 309-19 (2000).
11. Butterfield DA. P-Amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Chem Res Toxicol 10: 495-506 (1997).
12. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23: 134-47 (1997).
13. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid P-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43: 658-77 (2007).
14. Markesbery WR. Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18: S13-9 (1997).
15. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid P-peptide. Trends Mol Med 7: 548-54 (2001).
16. Glabe CC. Amyloid accumulation and pathogensis of Alzheimer's disease: Significance of monomeric, oligomeric and fibrillar Ap. Subcell Biochem 38: 167-77 (2005).
17. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of AP(1-42). J Neurochem 78: 413-6 (2001).
18. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid P-peptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-60 (2002).
19. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23: 655-64 (2002).
20. Yatin SM, Varadarajan S, Butterfield DA. Vitamin E prevents Alzheimer's amyloid P-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2: 123-31 (2000).
21. Butterfield DA, Koppal T, Subramaniam R, Yatin S. Vitamin E as an antioxidant/free radical scavenger against amyloid P-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: Insights into Alzheimer's disease. Rev Neurosci 10: 141-9 (1999).
22. Yokota T, Igarashi K, Uchihara T, Jishage K, Tomita H, Inaba A, et al. Delayed-onset ataxia in mice lacking a -tocopherol transfer protein: Model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci USA 98: 15185-90 (2001).
23. Nishida Y, Yokota T, Takahashi T, Uchihara T, Jishage K, Mi-zusawa H. Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. Biochem Biophys Res Commun 350: 530-6 (2006).
24. Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, et al. Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem 284: 33400-8 (2009).
25. Gaedicke S, Zhang X, Huebbe P, Boesch-Saadatmandi C, Lou Y, Wiswedel I, et al. Dietary vitamin E, brain redox status and expression of Alzheimer's disease-relevant genes in rats. Br J Nutr 102: 398-406 (2009).
26. Chen LR, Thacker RR, Chow CK. Tissue antioxidant status and related enzymes in rats with long term vitamin E deficiency. Nutr Rep Int 22: 873-81 (1980).
27. De AK, Darad R. Physiological antioxidants and antioxidative enzymes in vitamin E-deficient rats. Toxicol Lett 44: 47-54 (1988).
28. Harrison FE, Allard J, Bixler R, Usoh C, Li L, May JM, et al. Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr Neurosci 12: 203-18 (2009).
29. Clement M, Dinh L, Bourre JM. Uptake of dietary RRR-α- and RRR-γ-tocopherol by nervous tissues, liver and muscle in vitamin-E-deficient rats. Biochim Biophys Acta 1256: 175-80 (1995).
30. Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, et al. α-Tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: Dose-response study and correlations with plasma levels. Neurology 47: 1037-42 (1996).
31. Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 51: 621-3 (1988).
32. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Ag-garwal NT, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81: 508-14 (2005).
33. Mishima K, Tanaka T, Pu F, Egashira N, Iwasaki K, Hidaka R et al. Vitamin E isoforms α-tocotrienol and γ-tocopherol prevent cerebral infarction in mice. Neurosci Lett 337: 56-60 (2003).
34. Jiang Q, Ames BN. γ-Tocopherol, but not α-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 17: 816-22 (2003).
35. Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR et al. The nitration product 5-nitro-γ-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6: 221-7 (2002).
36. Morton LW, Ward NC, Croft KD, Puddey IB. Evidence for the nitration of γ-tocopherol in vivo: 5-nitro-γ-tocopherol is elevated in the plasma of subjects with coronary heart disease. Biochem J 364: 625-8 (2002).
37. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18: 8126-32 (1998).
38. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral α-tocopherol supplements decrease plasma γ-tocopherol levels in humans. J Nutr 115: 807-13 (1985).
39. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13: 444 (2002).
40. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y, et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 150: 37-44 (1999).
41. Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller-Thomsen T, et al. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31: 345-54 (2001).
42. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, et al. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Phar-macother 39: 2009-14 (2005).
43. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 159: 959-67 (2004).
44. Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60: 203-8 (2003).
45. Nourhashemi F, Gillette-Guyonnet S, Andrieu S, Ghisolfi A, Ous-set PJ, Grandjean H, et al. Alzheimer disease: Protective factors. Am J Clin Nutr 71: 643S-649S (2000).
46. Chandra RK. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 17: 709-12 (2001).
47. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 61: 82-8 (2004).
48. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12: 121-6 (1998).
49. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287: 3223-9 (2002).
50. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grund-man M, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336: 1216-22 (1997).
51. Tabet N BJ, Evans JG, Orrel M, Spector A. Vitamin E for Alzheimer's disease. Cochrane Database Syst. Rev 4: CD002854 (2000).
52. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J. Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17: 143-9 (2009).
53. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: Implications for accumulation of reactive lipid peroxidation products. Neurochem Res 29: 2215-20 (2004).
54. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M. ATP-and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126: 681-8 (1999).
55. Chrestensen CA, Starke DW, Mieyal JJ. Acute cadmium exposure inactivates thioltransferase (Glutaredoxin), inhibits intracellular reduction of protein-glutathionyl-mixed disulfides, and initiates apoptosis. J Biol Chem 275: 26556-65 (2000).
56. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, et al. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85: 1506-14 (2007).
57. di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, et al. Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: Implications for AD pathogenesis. Neurochem Res 34: 727-33 (2009).
58. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related protein 2, α-enolase and heat shock cognate 71. J Neurochem 82: 1524-32 (2002).
59. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33: 562-71 (2002).
60. Sultana R, Perluigi M, Butterfield DA. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Aβ(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 833: 3-11 (2006).
61. Vanhanen M, Soininen H. Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol 11: 673-7 (1998).
62. Liu R, Choi J. Age-associated decline in γ-glutamylcysteine synthetase gene expression in rats. Free Radic Biol Med 28: 566-74 (2000).
63. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8: 1975-86 (2006).
64. Petersen RC. Mild cognitive impairment: Transition between aging and Alzheimer's disease. Neurologia 15: 93-101 (2000).
65. Portet F, Ousset PJ, Touchon J. [What is a mild cognitive impairment?]. Rev Prat 55: 1891-4 (2005).
66. Sultana R, Piroddi M, Galli F, Butterfield DA. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33: 2540-6 (2008).
67. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51: 1562-6 (1998).
68. Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med 25: 979-88 (1998).
69. Anderson ME, Luo JL. Glutathione therapy: From prodrugs to genes. Semin Liver Dis 18: 415-24 (1998).
70. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants α-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84: 1173-83 (2003).
71. Koppal T, Drake J, Butterfield DA. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim Biophys Acta 1453: 407-11 (1999).
72. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39: 141-9 (2001).
73. Pocernich CB, La Fontaine M, Butterfield DA. In vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int 36: 185-91 (2000).
74. Fu AL, Dong ZH, Sun MJ. Protective effect of N-acetyl-L-cysteine on amyloid P-peptide-induced learning and memory deficits in mice. Brain Res 1109: 201-6 (2006).
75. Bartov O, Sultana R, Butterfield DA, Atlas D. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from AP(1-42) toxicity. Brain Res 1069: 198-206 (2006).
76. Xu Y, Hou XY, Liu Y, Zong YY. Different protection of K252a and N-acetyl-L-cysteine against amyloid-P peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. J Neurosci Res 87: 918-27 (2009).
77. Hsiao YH, Chen PS, Yeh SH, Lin CH, Gean PW. N-acetylcysteine prevents P-amyloid toxicity by a stimulatory effect on p35/cyclin-dependent kinase 5 activity in cultured cortical neurons. J Neurosci Res 86: 2685-95 (2008).
78. Yan CY, Greene LA. Prevention of PC 12 cell death by N-acetylcysteine requires activation of the Ras pathway. J Neurosci 18: 4042-9 (1998).
79. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, et al. Aggregated amyloid-P protein induces cortical neuronal apoptosis and concomitant apoptotic pattern of gene induction. J Neurosci 17: 7736-45 (1997).
80. Studer R, Baysang G, Brack C. N-Acetyl-L-cysteine downregulates P-amyloid precursor protein gene transcription in human neuroblastoma cells. Biogerontology 2: 55-60 (2001).
81. Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetylcysteine. Curr Alzheimer Res 3: 221-7 (2006).
82. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, Brockhaus M, et al. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: Effects on P-amyloid secretion and tau phosphorylation. J Neurochem 76: 224-33 (2001).
83. Xiao L, Zhao D, Chan WH, Choi MM, Li HW. Inhibition of P 1-40 amyloid fibrillation with N-acetyl-L-cysteine capped quantum dots. Biomaterials 31: 91-8 (2010).
84. Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 64: 378-85 (2005).
85. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 310: 236-41 (2003).
86. Wang R, Malter JS, Wang DS. N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-P-induced modification and inacti-vation of neprilysin in SH-SY5Y cells. J Alzheimers Dis 19: 179-89 (2010).
87. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57: 1515-7 (2001).
88. Remington R, Chan A, Paskavitz J, Shea TB. Efficacy of a vita-min/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: A placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 24: 27-33 (2009).
89. Anderson ME, Meister A. Transport and direct utilization of γ-glutamylcyst(e)ine for glutathione synthesis. Proc Natl Acad Sci USA 80: 707-11 (1983).
90. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA. Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 68: 776-84 (2002).
91. Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA. γ-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against AP(1-42)-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. J Neurosci Res 79: 700-6 (2005).
92. Boyd-Kimball D, Sultana R, Poon HF, Mohmmad-Abdul H, Lynn BC, Klein JB, et al. γ-glutamylcysteine ethyl ester protection of proteins from AP(1-42)-mediated oxidative stress in neuronal cell culture: A proteomics approach. J Neurosci Res 79: 707-13 (2005).
93. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23: 5088-95 (2003).
94. Medina S, Martinez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor a, dopamine and P-amyloid peptide 1-42. Free Radic Res 36: 1179-84 (2002).
95. Barber VS, Griffiths HR. Is glutathione an important neuroprotective effector molecule against amyloid P toxicity? Biofactors 17: 215-28 (2003).
96. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radic Biol Med 22: 359-78 (1997).
97. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 33: 385-97 (1992).
98. Seaton TA, Jenner P, Marsden CD. The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. Biochem Pharmacol 51: 983-6 (1996).
99. Ishii K, Minoshima S. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for. Eur J Nucl Med Mol Imaging 32: 1463-5 (2005).
100. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid P-peptide and iron/hydrogen peroxide toxicity by α-lipoic acid. J Alzheimers Dis 5: 229-39 (2003).
101. Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, et al. α-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett 312: 125-8 (2001).
102. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neu-robiol Aging 18: 457-61 (1997).
103. Lovell MA, Xie C, Markesbery WR. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic Biol Med 29: 714-20 (2000).
104. Pocernich CB, Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease. Neurotox Res 5: 515-20 (2003).
105. Arivazhagan P, Ramanathan K, Panneerselvam C. Effect of DL-alpha-lipoic acid on glutathione metabolic enzymes in aged rats. Exp Gerontol 37: 81-7 (2001).
106. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72: 115-9 (1986).
107. Haugaard N, Levin RM. Regulation of the activity of choline acetyl transferase by lipoic acid. Mol Cell Biochem 213: 61-3 (2000).
108. Haugaard N, Levin RM. Activation of choline acetyl transferase by dihydrolipoic acid. Mol Cell Biochem 229: 103-6 (2002).
109. Jarrett JT, Lansbury PT. Seeding one-dimensional crystallization of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-8 (1993).
110. Ono K, Hirohata M, Yamada M. α-Lipoic acid exhibits anti-amyloidogenicity for P-amyloid fibrils in vitro. Biochem Biophys Res Commun 341: 1046-52 (2006).
111. Jesudason EP, Masilamoni JG, Ashok BS, Baben B, Arul V, Jesu-doss KS, et al. Inhibitory effects of short-term administration of DL-α-lipoic acid on oxidative vulnerability induced by AP amyloid fibrils (25-35) in mice. Mol Cell Biochem 311: 145-56 (2008).
112. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 101: 3381-6 (2004).
113. Suh JH, Wang H, Liu RM, Liu J, Hagen TM. (R)-α-Lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: Evidence for increased cysteine requirement for GSH synthesis. Arch Biochem Biophys 423: 126-35 (2004).
114. Yagi H, Katoh S, Akiguchi I, Takeda T. Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res 474: 86-93 (1988).
115. Flood JF, Morley JE. Age-related changes in footshock avoidance acquisition and retention in senescence accelerated mouse (SAM). Neurobiol Aging 14: 153-7 (1993).
116. Fujibayashi Y, Yamamoto S, Waki A, Konishi J, Yonekura Y. Increased mitochondrial DNA deletion in the brain of SAMP8, a mouse model for spontaneous oxidative stress brain. Neurosci Lett 254: 109-12 (1998).
117. Hensley K, Carney J, Hall N, Shaw W, Butterfield DA. Electron paramagnetic resonance investigations of free radical-induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Radic Biol Med 17: 321-31 (1994).
118. Bickford PC, Gould T, Briederick L, Chadman K, Pollock A, Young D, et al. Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. Brain Res 866: 211-7 (2000).
119. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic acid. Proc Natl Acad Sci USA 99: 2356-61 (2002).
120. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, et al. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res 43: 156-64 (2009).
121. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behav Genet 29: 177-85 (1999).
122. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, et al. Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28: 213-25 (2007).
123. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. α-Lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr 32: 275-82 (2001).
124. Hager K, Kenklies M, McAfoose J, Engel J, Munch G. α-Lipoic acid as a new treatment option for Alzheimer's disease -- A 48 months follow-up analysis. J Neural Transm Suppl 189-93 (2007).
125. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 130: 2073S-2085S (2000).
126. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32: 1141-8 (1983).
127. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62: 1276-82 (1995).
128. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56: 545-53 (2000).
129. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver P-glucosidase activity. FEBS Lett 436: 71-5 (1998).
130. Gee JM, DuPont MS, Rhodes MJ, Johnson IT. Quercetin gluco-sides interact with the intestinal glucose transport pathway. Free Radic Biol Med 25: 19-25 (1998).
131. Walgren RA, Karnaky KJ, Lindenmayer GE, Walle T. Efflux of dietary flavonoid quercetin 4'-P-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294: 830-6 (2000).
132. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30: 433-46 (2001).
133. Hanasaki Y, Ogawa S, Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16: 845-50 (1994).
134. Haenen GR, Bast A. Nitric oxide radical scavenging of flavonoids. Methods Enzymol 301: 490-503 (1999).
135. Haenen GR, Paquay JB, Korthouwer RE, Bast A. Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun 236: 591-3 (1997).
136. Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of P-amyloid. J Agric Food Chem 53: 8537-41 (2005).
137. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87: 172-81 (2003).
138. Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA. Protective effect of quercetin in primary neurons against AP(1-42): Relevance to Alzheimer's disease. J Nutr Biochem 20: 269-75 (2009).
139. Boots AW, Haenen GR, Bast A. Health effects of quercetin: From antioxidant to nutraceutical. Eur J Pharmacol 585: 325-37 (2008).
140. Galati G, Moridani MY, Chan TS, O'Brien PJ. Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: Glutathione oxidation and conjugation. Free Radic Biol Med 30: 370-82 (2001).
141. Awad HM, Boersma MG, Boeren S, van der Woude H, van Zanden J, van Bladeren PJ, et al. Identification of o-quinone/quinone me-thide metabolites of quercetin in a cellular in vitro system. FEBS Lett 520: 30-4 (2002).
142. Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, et al. The quercetin paradox. Toxicol Appl Pharmacol 222: 89-96 (2007).
143. Boots AW, Balk JM, Bast A, Haenen GR. The reversibility of the glutathionyl-quercetin adduct spreads oxidized quercetin-induced toxicity. Biochem Biophys Res Commun 338: 923-929 (2005).
144. Ueno I, Nakano N, Hirono I. Metabolic fate of [14C] quercetin in the ACI rat. Jpn J Exp Med 53: 41-50 (1983).
145. Mullen W, Graf BA, Caldwell ST, Hartley RC, Duthie GG, Edwards CA, et al. Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4'-glucoside. J Agric Food Chem 50: 6902-9 (2002).
146. Morrice PC, Wood SG, Duthie GG. High-performance liquid chromatographic determination of quercetin and isorhamnetin in rat tissues using P-glucuronidase and acid hydrolysis. J Chromatogr B Biomed Sci Appl 738: 413-7 (2000).
147. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, Alink GM, et al. Tissue distribution of quercetin in rats and pigs. J Nutr 135: 1718-25 (2005).
148. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 36: 592-604 (2004).
149. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res 53: 5977-81 (1993).
150. Sarkar MA. Quercetin not only inhibits P-glycoprotein efflux activity but also inhibits CYP3A isozymes. Cancer Chemother Pharmacol 36: 448-50 (1995).
151. Pervaiz S. Resveratrol: From grapevines to mammalian biology. FASEB J 17: 1975-85 (2003).
152. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-47 (2002).
153. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111-8 (2009).
154. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33: 387-98 (2002).
155. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115: 194-201 (2005).
156. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, et al. AMPK signaling activation by resveratrol modulates amyloid-P peptide metabolism. J Biol Chem (2010).
157. Miller NJ, Rice-Evans CA. Antioxidant activity of resveratrol in red wine. Clin Chem 41: 1789 (1995).
158. Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 53: 6-15 (2006).
159. Robb EL, Page MM, Wiens BE, Stuart JA. Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. Biochem Biophys Res Commun 367: 406-12 (2008).
160. Kim HJ, Lee KW, Lee HJ. Protective effects of piceatannol against P-amyloid-induced neuronal cell death. Ann NY Acad Sci 1095: 473-82 (2007).
161. Jang JH, Surh YJ. Protective effect of resveratrol on P-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34: 1100-10 (2003).
162. Conte A, Pellegrini S, Tagliazucchi D. Synergistic protection of PC 12 cells from P-amyloid toxicity by resveratrol and catechin. Brain Res Bull 62: 29-38 (2003).
163. Feng Y, Wang XP, Yang SG, Wang YJ, Zhang X, Du XT, et al. Resveratrol inhibits P-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30: 986-95 (2009).
164. Klein WL, Stine WB, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25: 569-80 (2004).
165. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67: 27-37 (2006).
166. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15: 506-16 (2004).
167. Bisht K, Wagner KH, Bulmer AC. Curcumin, resveratrol and fla-vonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology (2009).
168. Jang MH, Piao XL, Kim HY, Cho EJ, Baek SH, Kwon SW, et al. Resveratrol oligomers from Vitis amurensis attenuate P-amyloid-induced oxidative stress in PC12 cells. Biol Pharm Bull 30: 1130-4 (2007).
169. Jang MH, Piao XL, Kim JM, Kwon SW, Park JH. Inhibition of cholinesterase and amyloid-P aggregation by resveratrol oligomers from Vitis amurensis. Phytother Res 22: 544-9 (2008).
170. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-P peptides. J Biol Chem 280: 37377-82 (2005).
171. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-9 (2000).
172. Gregori L, Fuchs C, Figueiredo-Pereira ME, van Nostrand WE, Goldgaber D. Amyloid P-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 270: 19702-8 (1995).
173. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, et al. Moderate consumption of Cabernet Sauvignon attenuates AP neuropathology in a mouse model of Alzheimer's disease. FASEB J 20: 2313-20 (2006).
174. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study. Neurology 59: 1313-9 (2002).
175. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R et al. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 153: 185-92 (1997).
176. Dorozynski A. Wine may prevent dementia. BMJ 314: 997 (1997).
177. Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc 52: 540-6 (2004).
178. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28: 6388-92 (2008).
179. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, et al. Grape-derived polyphenolics prevent AP oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28: 6388-92 (2008).
180. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, et al. Effects of grape seed-derived polyphenols on amyloid P-protein self-assembly and cytotoxicity. J Biol Chem 283: 32176-87 (2008).
181. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. SIRT1 transgenic mice show phenotypes resembling calo rie restriction. Aging Cell 6: 759-67 (2007).
182. Hyun DH, Emerson SS, Jo DG, Mattson MP, de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci USA 103: 19908-12 (2006).
183. Mattson MP. Will caloric restriction and folate protect against AD and PD? Neurology 60: 690-5 (2003).
184. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227-30 (2001).
185. You H, Mak TW. Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4: 37-8 (2005).
186. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37: 349-50 (2005).
187. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-2 (2004).
188. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-P toxicity through inhibiting NF-kB signaling. J Biol Chem 280: 40364-74 (2005).
189. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegen-eration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26: 3169-79 (2007).
190. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281: 21745-54 (2006).
191. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Sac-charomyces cerevisiae lifespan. Nature 425: 191-6 (2003).
192. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev 126: 987-1002 (2005).
193. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-9 (2004).
194. Lamming DW, Wood JG, Sinclair DA. Small molecules that regulate lifespan: Evidence for xenohormesis. Mol Microbiol 53: 1003-9 (2004).
195. Albani D, Polito L, Batelli S, de Mauro S, Fracasso C, Martelli G, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α-synuclein or amy-loid-P(1-42) peptide. J Neurochem 110: 1445-56 (2009).
196. Anekonda TS. Resveratrol -- A boon for treating Alzheimer's disease? Brain Res Rev 52: 316-26 (2006).
197. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283: 27628-35 (2008).
198. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187-95 (2005).
199. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104: 7217-22 (2007).
200. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMPK-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes (2009).
201. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol 57: 824-30 (2000).
202. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem (2009).
203. Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 14: 175-85 (1989).
204. Wei QY, Chen WF, Zhou B, Yang L, Liu ZL. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by cur-cumin and its analogues. Biochim Biophys Acta 1760: 70-7 (2006).
205. Shih CA, Lin JK. Inhibition of 8-hydroxydeoxyguanosine formation by curcumin in mouse fibroblast cells. Carcinogenesis 14: 709-12 (1993).
206. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6: 367-77; discussion 443-9 (2004).
207. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 19: 636-47 (2009).
208. Nishinaka T, Ichijo Y, Ito M, Kimura M, Katsuyama M, Iwata K, et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 170: 238-47 (2007).
209. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bel-lia F, et al. Cellular stress response: A novel target for chemopre-vention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 33: 2444-71 (2008).
210. Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res 52: 1062-73 (2008).
211. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-7 (2001).
212. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al. Phenolic anti-inflammatory antioxidant reversal of AP-induced cognitive deficits and neuropathology. Neurobiol Aging 22: 993-1005 (2001).
213. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's P-amyloid fibrils in vitro. J Neurosci Res 75: 742-50 (2004).
214. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambe-gaokar SS, et al. Curcumin inhibits formation of amyloid P oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-901 (2005).
215. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102: 1095-104 (2007).
216. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psy-chopharmacol 28: 110-3 (2008).
217. Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 91: 1199-210 (2004).
218. Higdon JV, Frei B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43: 89-143 (2003).
219. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neu-rosignals 14: 46-60 (2005).
220. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78: 1073-82 (2001).
221. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC. Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res 75: 261-74 (2007).
222. Guo Q, Zhao B, Li M, Shen S, Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304: 210-22 (1996).
223. Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, Hara Y. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21: 895-902 (1996).
224. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 322: 339-46 (1995).
225. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against P-amyloid-induced toxicity. Eur J Neurosci 23: 55-64 (2006).
226. Ban JY, Jeon SY, Bae K, Song KS, Seong YH. Catechin and epi-catechin from Smilacis chinae rhizome protect cultured rat cortical neurons against amyloid-P protein (25-35)-induced neurotoxicity through inhibition of cytosolic calcium elevation. Life Sci 79: 2251-9 (2006).
227. Bastianetto S, Dumont Y, Han Y, Quirion R. Comparative neuroprotective properties of stilbene and catechin analogs: Action via a plasma membrane receptor site? CNS Neurosci Ther 15: 76-83 (2009).
228. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against AP toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 17: 952-4 (2003).
229. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25: 8807-14 (2005).
230. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces P-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214: 177-87 (2008).
231. Haque AM, Hashimoto M, Katakura M, Hara Y, Shido O. Green tea catechins prevent cognitive deficits caused by AP(1-40) in rats. J Nutr Biochem 19: 619-26 (2008).
232. Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis 15: 211-22 (2008).
233. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, et al. PKC8 increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 103: 8215-20 (2006).
234. Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, et al. Green tea consumption and cognitive function: A cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 83: 355-61 (2006).
235. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study. JAMA 296: 1255-65 (2006).
236. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Long-streth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155: 732-8 (2002).
237. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 22: 2242-8 (2007).
238. Kanski J, Aksenova M, Stoyanova A, Butterfield DA. Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: Structure-activity studies. J Nutr Biochem 13: 273-81 (2002).
239. Kikuzaki H, Hisamoto M, Hirose K, Akiyama K, Taniguchi H. Antioxidant properties of ferulic acid and its related compounds. J Agric Food Chem 50: 2161-8 (2002).
240. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butter-Field DA. Ferulic acid ethyl ester protects neurons against amyloid P- peptide(1-42)-induced oxidative stress and neurotoxicity: Relationship to antioxidant activity. J Neurochem 92: 749-58 (2005).
241. Joshi G, Perluigi M, Sultana R, Agrippino R, Calabrese V, Butter-field DA. In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): Insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochem Int 48: 318-27 (2006).
242. Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R et al. In vivo protective effects of ferulic acid ethyl ester against amyloid-P peptide 1-42-induced oxidative stress. J Neurosci Res 84: 418-26 (2006).
243. Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal 6: 811-8 (2004).
244. Combs CK, Karlo JC, Kao SC, Landreth GE. P-Amyloid stimulation of microglia and monocytes results in TNFa-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21: 1179-88 (2001).
245. Hu J, Akama KT, Krafft GA, Chromy BA, van Eldik LJ. Amyloid-P peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195-206 (1998).
246. Hosoda A, Ozaki Y, Kashiwada A, Mutoh M, Wakabayashi K, Mizuno K, et al. Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity. Bioorg Med Chem 10: 1189-96 (2002).
247. Murakami A, Kadota M, Takahashi D, Taniguchi H, Nomura E, Hosoda A, et al. Suppressive effects of novel ferulic acid derivatives on cellular responses induced by phorbol ester, and by combined lipopolysaccharide and interferon-y. Cancer Lett 157: 77-85 (2000).
248. Maines MD. The heme oxygenase system and its functions in the brain. Cell Mol Biol (Noisy-le-grand) 46: 573-85 (2000).
249. Calabrese V, Stella AM, Butterfield DA, Scapagnini G. Redox regulation in neurodegeneration and longevity: Role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal 6: 895-913 (2004).
250. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, et al. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids 25: 437-44 (2003).
251. Schipper HM. Heme oxygenase-1: Role in brain aging and neurodegeneration. Exp Gerontol 35: 821-30 (2000).
252. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res 528: 21-4 (1990).
253. Chopp M, Chen H, Ho KL, Dereski MO, Brown E, Hetzel FW, et al. Transient hyperthermia protects against subsequent forebrain ischemic cell damage in the rat. Neurology 39: 1396-8 (1989).
254. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, et al. Protection against P-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133: 89-96 (2001).
255. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23: 81-8 (1998).
256. Mohmmad Abdul H, Butterfield DA. Protection against amyloid P-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: Implications for Alzheimer's disease. Bio-chim Biophys Acta 1741: 140-8 (2005).
257. Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg Med Chem Lett 18: 2905-9 (2008).
258. Hudson SA, Ecroyd H, Kee TW, Carver JA. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 276: 5960-72 (2009).